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Objective: Predicting who responds to placebo treatment—and under which
circumstances—has been a question of interest and investigation for generations.
However, the literature isdisparateand inconclusive.This reviewaimsto identifypublications
that provide high quality data on the topic of placebo response (PR) prediction.
Methods: To identify studies concerned with PR prediction, independent searches were
performed in an expert database (for all symptom modalities) and in PubMed (for pain
only). Articles were selected when (a) they assessed putative predictors prior to placebo
treatment and (b) an adequate control group was included when the associations of
predictors and PRs were analyzed.
Results: Twenty studies were identified, most with pain as dependent variable. Most
predictors of PRs were psychological constructs related to actions, expected outcomes
and the emotional valence attached to these events (goal-seeking, self-efficacy/-esteem,
locus of control, optimism). Other predictors involved behavioral control (desire for control,
eating restraint), personality variables (fun seeking, sensation seeking, neuroticism),
or biological markers (sex, a single nucleotide polymorphism related to dopamine
metabolism). Finally, suggestibility and beliefs in expectation biases, body consciousness,
and baseline symptom severity were found to be predictive.
Conclusions: While results are heterogeneous, some congruence of predictors can be
identified. PRs mainly appear to be moderated by expectations of how the symptommight
change after treatment, or expectations of how symptom repetition can be coped with. It
is suggested to include the listed constructs in future research. Furthermore, a closer look
at variables moderating symptom change in control groups seems warranted.
Keywords: placebo, placebo response prediction, pain, optimism, self-efficacy, personality
BACKGROUND
Differences in placebo responsiveness have long been acknowl-
edged and the topic of much empirical scrutiny. Since the onset
of dedicated placebo research, the question of who does or does
not respond to sugar pills has been discussed (for reviews, see
Bootzin and Caspi, 2002; Kaptchuk et al., 2008). For some time,
responding to placebos was considered a stigma for various rea-
sons (Parkhouse, 1963; Brody and Brody, 2000). However, since
the grounding of placebo responses (PRs) in a less mentalis-
tic and more physiological framework—e.g., with the seminal
work of Levine et al. (1978), involving the endogenous opi-
oid system in placebo analgesia –, this stigmatization has par-
tially subsided, at least in academia (Thompson et al., 2009).
In recent years, especially with the widespread use of tech-
nology enabling the monitoring of brain activity, the respon-
der question has been reconciled with mechanistic approaches.
Consequently, interest in prediction of PRs was revived (Geers
et al., 2005a) and since sparked a number of dedicated studies.
Until recently however, the evidence supporting PR prediction
was still considered disparate (Kaptchuk et al., 2008; Benedetti,
2009). A better understanding of placebo mechanisms, and
therefore predictability of PRs, will allow for both the maxi-
mization and minimization of PRs. In established treatments,
maximizing the additional PR is desirable. However, in early
phases of pharmacological research, minimization and control
of PRs is an important issue, in order to isolate and prove
that a new treatment is effective beyond placebo (Enck et al.,
2013).
This review is concerned with collating studies of suffi-
cient methodological quality that address prediction of the
PR. Terminological uncertainties notwithstanding (Hróbjartsson,
2002), we regard the PR as a symptom improvement caused
by a placebo treatment and the context in which it is deliv-
ered. This causal relation is considered to be mediated mostly
by expectancy and related mechanisms (Finniss et al., 2010; Enck
et al., 2013). The core question to be addressed is: “Are the deter-
minants of placebo responsiveness located within or outside of
the individual?”
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Placebo responsiveness could constitute a stable trait (uni- or
multidimensional, e.g., a personality variable or genetic polymor-
phism). It would affect PRs independently of situational variables.
People could therefore be classified on a dimension ranging
from “responder” to “non-responder.” This point of view has
been especially prevalent during early investigations into placebo
responsiveness, but results have been inconclusive (Gryll and
Katahn, 1978; Bootzin and Caspi, 2002).
To the contrary, the working model of most clinical trials—but
also of many dedicated placebo studies—pragmatically empha-
sizes the fluctuating, situational determination of PRs. In fact, this
is the implicit default assumption when determinants of PRs are
not further considered in a study. Situational determinants can be
generated outside (e.g., experimental manipulation) or inside the
individual (e.g., mood). In this model, everybody is a potential
responder, placebo responsiveness is ubiquitous and activated by
situational influences (Bootzin and Caspi, 2002).
These simple explanations have merit to a certain degree: On
the one hand, temperament, personality traits etc. by definition
produce consistent behavioral output even in changing environ-
ments (Rothbart, 2007). On the other hand, sufficiently strong
situations do have the ability to normalize a range of behaviors
(Snyder and Ickes, 1985). However, most psychological charac-
teristics conform to amore interactional view (David et al., 1997).
This is reflected in the third basic explanation, which emphasizes
how different trait variables interact with different situational
variables to explain the extent of placebo responsiveness (Geers
et al., 2007). Frequently, the focus of these approaches in placebo
research lies on the therapeutic relationship and the quality of
the interaction (Shapiro, 1971; Frank and Frank, 1973; Gryll and
Katahn, 1978).
The latter concept can be elaborated by pointing out how
PRs feed back to influence their determinants in future instances.
This emphasizes possible changes in responsiveness over time and
thereby the relevance of medical experience and socialization (the
long-term dispositional and situational requirements to be met
for placebo responsiveness to develop) (Moerman, 2000).
DEDUCTION OF INCLUSION CRITERIA
In the following, the rationale for inclusion of studies in the
review is described. We use the term “predictor” to describe mod-
erating variables measured prior to the placebo instruction, which
are able to predict the response to placebo at a later time. In
other words, we are solely looking at determinants of placebo
responsiveness. Variables influenced by the placebo instruction
(mediators or “proximal factors” such as expectancy, Vase et al.,
2003) are not considered predictors along these lines.
Methodological inclusion criteria for valid statements concerning
prediction of placebo effects
Not all study designs or data analyses permit internally valid state-
ments about predictors of PRs. For example, the widely used
cross-over design has been criticized on various grounds. In a
cross-over design, all subjects are sequentially exposed tomultiple
or all experimental conditions; often, the design is counterbal-
anced, meaning that all permutations of condition orders are
included (Grizzle, 1965). While generally advantageous in terms
of statistical power, cross-over designs are prone to carry-over
effects—even in counterbalanced designs, where asymmetric skill
transfer can occur (Poulton and Freeman, 1966). Furthermore,
large within-subject variability (as has been reported in placebo
effects) and possible behavioral conditioning jeopardize internal
validity (Enck et al., 2013).
Several design aspects enhance internal validity by abolishing
many of the PRs’ confounders; the guiding principle being how
to assess the symptom change that would have happened in an
untreated group anyway, simply by virtue of time, study partic-
ipation, etc. (Hróbjartsson et al., 2011). Only studies including
one or more of the following aspects will be considered sufficient
to contribute to the responder discussion:
• No-treatment control group, a group receiving no treatment
at all, but an otherwise identical protocol. Despite frequently
being the best option, the certainty of not receiving anything
leads to a mindset quite different from the placebo group,
reducing actual comparability (Hróbjartsson, 2002)—the no-
treatment group cannot be blinded.Within the scope of clinical
trials, ethical and pragmatic reasons apply why a no-treatment
control (“natural history”) is rarely possible (Benedetti, 2009).
• “Open label” control group, where participants are being applied
the placebo, but are correctly informed that it is only an inert
treatment. This approach has the shortcoming that an instruc-
tion of inertness does not necessarily induce the expectation of
inertness—a participant might question whether the instruc-
tion is true and suspect the possibility that he or she is actually
being deceived. Furthermore, conditioning mechanisms could
be triggered regardless of information.
• While not strictly a design aspect, a known natural course of
symptoms amounts to an effective control condition (Benedetti,
2009). For example, knowing that symptoms in a specific med-
ical condition either remain constant or worsen, any significant
improvement in the placebo group would at least preclude
spontaneous remission. However, to “know” a course requires
having measured it at some time, therefore constituting a his-
torical control group likewise exposed to all biases inherent in
study participation. Caution has to be taken not to underesti-
mate the singular conditions of each study in terms of sample,
setting etc. (Hróbjartsson, 2002).
• Different levels of placebo manipulations. While not permitting
conclusions regarding the absolute size of PRs, different levels
of independent placebo variables arguably permit relative state-
ments, e.g., “two pills are more effective than one.” Therefore,
the interaction between predictors of interest and the placebo
manipulation can be examined.
Statistical inclusion criteria for valid statements concerning
prediction of placebo effects
If an adequate control condition has been established, it has to
be duly considered in statistical analysis. Not all studies fulfill this
requirement, e.g., when predicting PRs only in the placebo group,
without considering the no-treatment control group in the same
regression (Lyby et al., 2010). In analogy to the determination of
the extent of PRs (which can only be achieved by comparison
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to an adequate control), this tells us little: After all, the correla-
tion of predictors and symptom change (pre- to post-placebo)
could be entirely due to natural history and various other effects
of measurement repetition. Even if the correlation is significant
in one group but not the other (e.g., Fillmore et al., 1998), it is
not guaranteed that there is a significant difference between the
two correlations. This would have to be established by methods
such as Fisher’s Z-test or regression analysis. Therefore, analyses
specifically aimed at PRs have to show differential prediction of
symptom change in placebo vs. control. Figure 1 shows the rele-
vance of examining this interaction. Once differential prediction
is established, the assessment allows for determination of whether
the correlation is divergent in both groups (A, B) or actually gets
associated (C), or dissociated (D) in the placebo group (for an
applied example, see Figure 1 of Handley et al., 2011). In par-
ticular, establishing differential prediction allows identification of
otherwise “silent” effects, when no significant correlations exist in
either placebo or control group (B).
MATERIALS AND METHODS
SEARCH STRATEGY AND CATEGORIZATION OF STUDIES
Two independent search strategies were used to identify studies
investigating determinants of placebo responsiveness. The first
search was performed in a database established in 2004 by our
group. At the inception of this database, about 100.000 cita-
tions from PubMed were retrospectively examined for dedicated
treatment of the PR by using the search string “placebo.” Excluded
were “randomized placebo-controlled trials. . . , editorials, letters
to the editor and review papers and meta-analyses not related to
FIGURE 1 | Conceptual illustration of some possible interactions
between predictor(s) and symptom change in placebo group (PG)
and control group (CG). Each regression slope represents a
correlation between a predictor (x-axis) and symptom change (y-axis) in
either PG or CG. The single regression slopes can be either significant
(as denoted by the asterisk) or not significant (n.s.). For valid placebo
response prediction, the two slopes must be significantly different, as
denoted by the asterisk next to the curly brackets. (A) Differential
association of predictors and symptom change in PG and CG (both
correlations significant but opposite, e.g., positive in PG, negative in
CG). (B) Subthreshold association (no correlation significant, only slope
difference). (C) Placebo-association (correlation significant in PG but not
CG). (D) Placebo-disassociation (correlation significant in CG but not PG).
the PR per se” (Enck et al., 2011). From 2004 on, new articles
were screened on a weekly basis. In January 2014, the database
contained 2540 dedicated placebo publications. The database
mainly contains publications researched via PubMed, published
in English, between 1953 and January 2014; however, papers from
numerous other sources are included.
Relevant publications were identified using methodologi-
cal descriptors (in title, abstract, or MeSH terms) indicative
of responder analyses such as “correl∗”, “predict∗”, “reactor”,
“regress∗”, or “respond∗”. After accounting for duplicates, the
database search yielded N = 605 publications. Via unsystematic
search of bibliographies and from various other sources, an addi-
tional 16 publications were identified for screening, totaling N =
621 (Figure 2A).
Of these publications, abstracts were examined and all but
original data papers were excluded. In detail, publications obvi-
ously not involving responder analyses were not considered, nor
were reviews, meta-analyses, or concept papers. For conceptual
clarity, nocebo studies were excluded as well, notwithstanding the
possible allocation of both placebo and nocebo on a single dimen-
sion (Petrovic, 2008; Scott et al., 2008). Furthermore, correlates
of PRs were excluded if no temporal sequence of predictor and
criterion was established by study protocol, i.e., if the putative
predictor was assessed after the placebo instruction. For exam-
ple, this concerns expectancy, or differences in endocrinological
or neuronal activation concurrent with the PR (Whalley et al.,
2008; Ober et al., 2011).
Of the subsequently identified 115 publications, Methods and
Results Sections were screened for adequacy in regard to the
methodological inclusion criteria outlined above, resulting in
further reduction to 32 articles. In the final step, statistical inclu-
sion criteria were applied and n = 12 publications remained (see
Figure 2A).
The second search strategy was performed in PubMed. It
used an exhaustive search string modified from Hróbjartsson and
FIGURE 2 | Flow diagram of study selection. A total of 15 publications
were included containing 20 (sub-)studies. (A) Placebo database search. (B)
Pubmed search.
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Gotzsche (2010) on English or German entries published before
February 2014. This string included general search terms as well
as MeSH terms, and was structured in three major segments:
• Segment one referred to “placebo” and variations like “sham”
• Segment two referred to data structure, statistical and method-
ological aspects like “association,” “correlation,” or “no-
treatment”
• Segment three referred to various exclusion criteria such as
non-original articles and animal experiments.
Furthermore, due to the large number of hits (>100.000), only
publications including “pain” or related terms like “analgesia”
were considered. The complete search strategy can be obtained
from the authors. Pain was chosen specifically because of the cen-
tral role it has for placebo research (Hoffman et al., 2005): Not
only does it have the largest empirical basis, but the method-
ologically soundest research has been considered to come from
this area.
The search yielded N = 8804 publications (Figure 2B).
Abstracts were examined one by one and a checklist for inclusion
was applied. Non-inclusions were tagged with justifications for
exclusion; since multiple tags could be assigned, there is a minor
overlap in exclusion categories. All dedicated placebo research
papers were included by default for the possibility of secondary
predictor analyses not mentioned in the abstract, except for 154
articles where it was clear from the abstract that a cross-over
design or no adequate control was used. Most excluded stud-
ies (n = 7717) were tagged as clinical studies which mentioned
placebo only as a control condition. 410 articles were excluded
for publication type (e.g., reviews, editorials). 459 studies were
excluded for study sample (e.g., animal research).
Selection resulted in n = 86 publications overall. Of these,
Methods and Results Sections were screened according to the
above inclusion criteria. 42 were excluded by virtue of not ana-
lyzing potential predictors mentioned in the abstract; 12 were
excluded due to not meetingmethodological inclusion criteria; 22
for not meeting statistical inclusion criteria; 1 article could not be
obtained. After experimental design and statistical analysis were
taken into account, 9 publications remained.
With an overlap of 6 publications, the second search con-
tributed 3 publications for a total of n = 15 considered in the
review. In these publications, a total of 20 (sub-)studies were
described and suited for predictor analysis (Tables 1, 2).
RESULTS
A general overview of the 15 articles is provided in Tables 1, 2.
Sub-studies are indicated by consecutive numbers as they
appeared in the respective publications, e.g., Heatherton et al.
(1989-2) for the publication’s second sub-study. Categorization
into stable/situational/interactional predictors is tentative, since
most psychological phenomena meet the criteria of more than
one category. Nine studies concerned with the identification of
PR predictors used experimental or clinical pain as a dependent
variable (Table 1). Three studies used cardiac parameters; two
studies each used affect, auditory discomfort, calorie intake and
sleep parameters, while one study each used caffeine symptoms
and motion sickness (Table 2). Overlap exists due to multiple
outcome variables.
TRAIT PREDICTORS OF PLACEBO RESPONSES
The statistical nature of the findings (being differentially pre-
dictive of PRs in the respective modality, as compared to an
adequate control) is shortened as “predictive.” Eleven studies were
identified which reported stable predictors.
Several psychological constructs predictive of PRs in vari-
ous modalities were closely related. As proposed (Geers et al.,
2005a), dispositional optimism significantly predicted placebo
analgesia in Geers et al. (2010). Geers et al. (2013) reported
that habitual desire for control predicted the PR on cold pain in
sub-study 1, and the PR on auditory discomfort in sub-study 2.
Furthermore, the investigators identified perceived stress as pre-
dictive for performance in a choice reaction time task. Darragh
et al. (2014) recently reported a significant prediction of change
in heart rate after placebo. Their regression model included pos-
itive interactions of group (placebo vs. control) with fun and
sensation seeking, and negative interactions of group and neu-
roticism. In a post-hoc analysis of one of our own studies (Horing
et al., 2013), we found an opposite effect of both self-efficacy
and internal locus of control: Higher scores predicted symptom
improvement in the control group but symptom worsening in
the placebo group (Horing, 2013). Another experiment by Geers’
group (Handley et al., 2011) found a lower belief in expectation
biases to be predictive of PRs–in other words, participants who
assumed expectation biases as less relevant concerning symptom
reports were actually more influenced by placebo instructions.
Lastly, Brockner and Swap (1983) found a higher body con-
sciousness (a psychological construct containing the extent and
precision of inward-directed attention), combined with low self-
esteem, as predictive of a “reverse placebo effect” on insomnia.
Study participants who were instructed that a pill had an arous-
ing effect actually relaxed better and had shorter sleep-onset
latency.
Putative biological markers identified for placebo responsive-
ness were participant sex and dopamine availability. In an unusual
design where a placebo instruction was used to facilitate condi-
tioned pain modulation, Bjorkedal and Flaten (2012) reported
that only women responded with increased analgesia. In a study
by Hall et al. (2012), increased PRs were associated with increased
dopamine availability as indexed by methionine alleles of the
val158met polymorphism.
SITUATIONAL AND INTERACTIONAL PREDICTORS OF PLACEBO
RESPONSES
In seven studies, five psychological predictors were identified with
clear internal situational, or interactional characteristics.
Contingent on the experimental manipulation, trait optimism
was found to significantly predict expectancy effects on sleep
quality in Geers et al. (2007)—with a positive correlation fol-
lowing placebo instruction, and an inverse correlation following
nocebo instruction.
Three of the five sub-studies reported by Geers et al. (2005b)
could be included in the review, namely sub-studies 1, 4,
and 5. They reported significantly increased PRs on various
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Table 1 | Studies investigating placebo response prediction in pain.
References N (f:m) Symptom or Placebo response Category
(sub-study) population variable predictor(s)
Bjorkedal and Flaten,
2011
23 (7:16) Paina intensity [No significant predictors]
Bjorkedal and Flaten,
2012
72 (36:36) Painb intensity Female sex Trait/stable
De Pascalis et al., 2002 72 (47:25) Painc intensity Match of suggestion and suggestibility
(SSS)
Interactional
Geers et al., 2010 116 (60:56) Overall paind Higher trait optimism (LOT-R) Trait/stable
Paind severity Higher trait optimism (LOT-R) Trait/stable
Paind intensity Higher trait optimism (LOT-R) Trait/stable
Geers et al., 2013-1 94 (62:32)* Paind intensity Higher habitual desire for control (DCS) Trait/stable
Hall et al., 2012 112 (83:29)
IBS patients
Paine and other
symptoms
Increased dopamine availability due to
methionine alleles
Trait/stable
Handley et al., 2011 49 (23:26) Paind intensity Lower belief in expectation biases (5-item
scale)
Trait/stable
Paind affect Lower belief in expectation biases (5-item
scale)
Trait/stable
Systolic blood
pressure
Higher belief in expectation biases (5-item
scale) lead to decrease in systolic blood
pressure
Trait/stable
Levine et al., 1979 107 (?:?)
OP patients
Painf severity Higher baseline symptom severity (VAS) Situational
Staats et al., 2001 48 (41:7) Paind intensity [No significant predictors]
Sub-studies are indicated by consecutive numbers as they appeared in the respective publications. Population consists of healthy students unless otherwise noted.
Placebo response predictors have been tentatively categorized into trait/stable characteristic, situational characteristic or interactional characteristic. As interaction
type according to Figure 1 could not be assessed from the majority of studies, no classification is performed. Example: Handley et al. (2011) investigated 49 healthy
participants and found that higher PR in cold pressor pain intensity and pain affect was predicted by lower belief in expectation biases, and that decrease in systolic
blood pressure was predicted by higher belief in expectation biases. Belief in expectation biases is considered a stable characteristic. Abbreviations: DCS, Desire
for Control Scale; IBS, Irritable Bowel Syndrome; LOT-R, revised Life Orientation Test; SSS, Sensory Suggestibility Scale.
*Overlap between sub-study samples not clear.
a−f Pain protocols: aLaser heat, bThermode heat, cElectrical, d Cold pressor, eClinical/symptomatic, f Postoperative.
symptoms (affect, caffeine effects, blood pressure) when the
participants were able to fulfill a goal (habitual or experi-
mentally instilled) by the confirmation of the placebo expec-
tation. For example, they used semantic priming to instill
a motive for cooperation, which the compliance with the
placebo instruction could fulfill. Geers et al. (2013-3) inves-
tigated PRs on auditory discomfort after desire for control
was experimentally induced. The association between desire
for control and the PR was only activated when there was a
possibility to choose between the (factually equivalent and inert)
treatments.
De Pascalis et al. (2002) found that suggestibility only exerted
significant influence on the PR in the stronger of two expec-
tation conditions; in the weaker condition, there was no dif-
ference between highly and lowly suggestible individuals. In a
rather unusual design, Heatherton et al. (1989-1 and 2) examined
whether calorie intake was differentially influenced by “placebo”
instructions by dietary restraint (i.e., abnormally monitoring
one’s eating behavior or following certain dietary restriction).
The instruction included the suggestion that participants either
felt hungry or full. Indeed, placebo instructions only worked in
the suggested direction in restrained eaters (eating more after the
“hungry”-pill, and less after the “full”-pill).
Among symptom- and pathology-related predictors, Levine
et al. (1979) reported a higher baseline pain severity as differ-
entially associated with placebo analgesia; this is the only study
which did not use a parametric outcome as dependent variable,
but a dichotomous responder definition.
NON-SIGNIFICANT PREDICTORS OF PLACEBO RESPONSES
Negative results were more difficult to ascertain. Single parame-
ters that were found not to be predictive of PRs in the respective
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Table 2 | Studies investigating placebo response prediction in symptoms other than pain.
References N (f:m) Symptom or Placebo response Category
(sub-study) population variable predictor(s)
Brockner and Swap, 1983 30 (?:?) Sleep onset Higher body consciousness Trait/stable
Insomniac students (minutes; self-report) Low self-esteem (revised Janis-Field
Self-Esteem Scale)
Trait/stable
Darragh et al., 2014 60 (41:19) Stress (heart rate Higher fun seeking (BIS/BAS scale) Trait/stable
change) Higher sensation seeking (BIS/BAS scale) Trait/stable
Lower neuroticism (EPQ-R Short Version) Trait/stable
Geers et al., 2005b-1 45 (21:24)* Affect Match of individual goals with possibility
to achieve goal by confirming placebo
expectation
Interactional
Geers et al., 2005b-4 57 (37:20)* Caffeine symptoms Match of individual goals with possibility
to achieve goal by confirming placebo
expectation
Interactional
Systolic blood
pressure
Match of individual goals with possibility
to achieve goal by confirming placebo
expectation
Interactional
Geers et al., 2005b-5 59 (35:24)* Affect Match of individual goals with possibility
to achieve goal by confirming placebo
expectation
Interactional
Geers et al., 2007 56 (38:18) Sleep quality Higher trait optimism (LOT-R) Trait/stable
Geers et al., 2013-2 98 (67:31)* Auditory discomfort Higher habitual desire for control (DCS) Trait/stable
Geers et al., 2013-3 121 (77:44)* Auditory discomfort Higher state desire for control (coding of
written manipulation check score)
Situational
Heatherton et al., 1989-1 129 (129:0)* Calorie intake High restraint (Restraint Scale) in
hungry-condition
Interactional
Heatherton et al., 1989-2 60 (60:0)* Calorie intake High restraint (Restraint Scale) in
hungry-condition
Interactional
Horing, 2013 28 (15:13) Motion sickness Lower generalized self-efficacy (GSE) Trait/stable
Lower internal locus of control (FKK) Trait/stable
For table structure see caption of Table 1. Abbreviations: BIS/BAS, Behavioral inhibition system/behavioral activation system; CFC, Consideration-of-Future-
Consequences scale; DCS, Desire for Control Scale; EPQ-R, revised Eysenck Personality Questionnaire; GSE, General Self-Efficacy scale; FKK, competence and
control belief scales [Fragenbogen zu Kompetenz und Kontrollüberzeugung]; LOT-R, revised Life Orientation Test.
*Overlap between sub-study samples not clear.
studies were the Fear of Pain Questionnaire (Bjorkedal and Flaten,
2012), Pain Anxiety Symptom Scale (Staats et al., 2001), revised
Life Orientation Test (Bjorkedal and Flaten, 2012; Horing, 2013)
as well as Beck Depression Inventory, Proactive Coping Inventory,
State-Trait Anxiety Inventory (all Horing, 2013), and participant
sex (Bjorkedal and Flaten, 2011). When single parameters were
mentioned, they were not or could not always be considered as
predictors. Among those mentioned but not analyzed were the
revised Self-Monitoring Scale (Handley et al., 2011), revised Life
Orientation Test (Handley et al., 2011; Darragh et al., 2014),
Consideration-of-Future-Consequences scale (Handley et al.,
2011), and Tellegen Absorption Scale (Darragh et al., 2014). In
addition to specific measures, three studies referred to “packets of
prescreening questionnaires [completed] earlier in the semester”
(Geers et al., 2010; Handley et al., 2011) or “a brief packet of
questionnaires” (Geers et al., 2007).
DISCUSSION
The prediction of PRs has been an endeavor of investigators from
the onset of dedicated research into the phenomenon. This review
attempted to assess the state of knowledge by applying conser-
vative methodological criteria for study inclusion. Surprisingly
few original papers prevailed—all in all, only 20 (sub-)studies
met the criteria. While it is possible that the search was overly
conservative, the goal was to identify only those studies from
which variables that differentially predicted symptom change in
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the placebo group vs. symptom change in the control group were
clearly distinguishable.
Results are heterogeneous, but imply that predictors are rather
not found among “classic” trait personality variables (such as
extraversion or neuroticism) or emotional response dispositions
(such as anxiety). Instead, they are more on the side of cognitive
constructs such as self-efficacy, locus of control, and “emotion-
alized” contingency expectations. From a theoretical perspective,
this is intuitive, considering how closely related these concepts are
to expectancy (Bandura, 1977). Expectancy is considered a major
PR mechanism (Finniss et al., 2010; Enck et al., 2013).
An important cluster seems to revolve around an internality-
externality dimension, such that participants follow placebo
instructions more readily when having an external locus of con-
trol. For example, results by Heatherton et al. (1989) have led the
investigators to hypothesize that restrained eaters lack sensitivity
to internal states and are therefore more reliant on external cues
to regulate behavior. The “permission” implicit in the placebo
instructions could provide such a cue. We propose that this readi-
ness is actually tied to low self-esteem (Brockner, 1988), which
would explain our own finding concerning predictors of PRs on
motion sickness (Horing, 2013). This interpretation is supported
by self-esteem moderation of PRs on sleep onset reported by
Brockner and Swap (1983).
Many of the mentioned constructs also draw attention to
potential sources of bias in repeated symptom measurements
and emphasize the necessity of careful experimental design when
investigating PRs. This notion is especially prevalent when con-
sidering results by Handley et al. (2011) involving the belief in
expectation biases in consequent placebo analgesia.
Due to its broad psychological ramifications, sex seems a less
tangible predictor of PRs. Debate is still open what relevance it
has for placebo responsiveness (Aslaksen et al., 2011). Results
presented here are mixed. Both psychological and biological
explanations for the positive predictive value of sex are offered
by Bjorkedal and Flaten (2012), albeit the paradigm used is
rather unusual (if intriguing), limiting comparability. In general,
it seems too convenient to restrict oneself to sex for psycho-
logically codetermined response variables like pain. Instead, it
seems worthwhile to include measures of (psychological) gender
to explore sociocultural influences.
It has been noted that there is not just one PR affecting all
symptommodalities, but many (Benedetti, 2009), potential over-
lap notwithstanding (Petrovic et al., 2005). This could explain
some of the heterogeneity—for example, the involvement of opti-
mism in pain and sleep quality (Geers et al., 2007, 2010), but
not in stress or motion sickness (Horing, 2013; Darragh et al.,
2014). This cautions one not to overgeneralize findings in single
symptom modalities, but instead try to describe the qualitative
characteristics of the investigated conditions. So far, the data base
for a symptom-specific assessment is thin. Pain would be themost
promising candidate for an isolated analysis.
As far as the characterization of placebo responsiveness as a
trait or state variable is concerned, this review offers little to
resolve the issue. We feel that a pattern is discernible which
warrants further investigation of stable characteristics such as per-
sonality variables. This is in line with other studies in the field
(Pecina et al., 2013) and does not contradict more interactional
oriented approaches (Kong et al., 2013).
We are confident of the reliability of the selection method. Yet,
this review has several limitations that need to be addressed. First,
the sample of studies examined for inclusion can be criticized.
Research has been mostly constrained to PubMed, resulting in
a probable bias for medical literature; more psychologically ori-
ented literature, as e.g., accessible via PsycInfo, was not included.
This shortcoming has to be eliminated by a more thorough,
dedicated research amounting to a systematic review or meta-
analysis. Secondly, publication bias is an important issue in
placebo research (Hróbjartsson et al., 2011) and certainly affects
this review, as well. Presumably, negative results in particular will
be underrepresented. Thirdly, inclusion criteria were rather con-
servative. Especially the exclusion of cross-over designs proved
to be a severe restriction, prohibiting consideration of pertinent
studies (e.g., Aslaksen et al., 2011; Pecina et al., 2013).
Yet, this concession is congruent with most authoritative
sources conceding a scarcity of reliable data concerning predic-
tors of placebo responsiveness (Kaptchuk et al., 2008; Benedetti,
2009). For example, Hall et al. (2012) implicated the reward
system in placebo responsiveness. While they corroborated pre-
vious evidence (Leuchter et al., 2009), the latter publication
could not be included due to lack of an adequate control.
Another article carried similar implications by reporting an asso-
ciation of gray matter density in reward sensitivity related brain
areas and PRs (Schweinhardt et al., 2009). Unfortunately, the
study used a cross-over design which was not considered for
inclusion in this review. Likewise, other studies did not have
sufficient validity regarding reward sensitivity (de la Fuente-
Fernandez et al., 2001; de la Fuente-Fernandez and Stoessl,
2002; Scott et al., 2007). Most relevantly, de la Fuente-Fernandez
et al. (2001) and de la Fuente-Fernandez and Stoessl (2002)
only assessed post-instruction associations of placebo responding
with reward sensitivity. As to the first study (de la Fuente-
Fernandez et al., 2001), sample size was very low (N = 6),
thereby not granting sufficient protection against chance results;
furthermore, carry-over effects seem likely, as far as the pro-
cedure could be ascertained. The second study did use a con-
trol group to assess novelty effects of first exposure to the
stimulus material, but no control incorporating the effects of
measurement repetition (de la Fuente-Fernandez and Stoessl,
2002). Scott et al. (2007) reported a correlation between Nucleus
accumbens-activity in placebo analgesia, and after monetary
reward. While the results are highly interesting and were well
received, the investigators did not include an adequate con-
trol group. Therefore, it cannot be precluded that simple mea-
surement repetition would have the same (or at least aligned)
effects.
Pertaining to the explanatory value of optimism, some pre-
cautions apply to the generalizability of these findings. On the
plus side, the effect has been analyzed with excellent method-
ology. However, results come only from a single research group
(Geers and colleagues) and should be replicated elsewhere.
Unfortunately, while Morton et al. (2009) investigated optimism
as well, they only performed an isolated analysis of the placebo
group. It should also be noted that other investigators found
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conflicting results compared to Geers’ group. For example, one
study did not replicate the interaction of optimism with a placebo
instruction, but only a main effect of optimism (Hanssen et al.,
2014). Relatedly, the induction of state optimism was found to
decrease pain (Hanssen et al., 2013), even though no placebo
was applied—effectively, this amounts to an optimism effect in
the control group, which did not show in the aforementioned
experiments. Darragh et al. (2014) did not find an association of
optimism with the PR on physiological stress parameters, nor did
we find an association with the PR on motion sickness (Horing,
2013).
A more basic criticism can be leveled at studies presented
by Geers and colleagues. Apparently, the basic efficacy of their
placebo paradigms has not been established—in three of five pub-
lications, main effects of condition (e.g., placebo vs. control) were
not significant (Geers et al., 2005b, 2007, 2010). Considering that
the efficacy of placebo has been established in many prior stud-
ies, it can be argued that a significant mean difference should
constitute a benchmark below which the symptom change in the
placebo group cannot be considered a PR.
On a more general note, the majority of studies were per-
formed with healthy undergraduate students, limiting generaliz-
ability in terms of age, medical condition, and other parameters.
Of the 20 studies reporting placebo predictors, nine were per-
formed by the same research group. Lastly, it is not guaranteed
that whatever predicts placebo responsiveness on one occasion
will be predictive at another—this applies to questions of relia-
bility, but also to the correspondence of psychological predictors
to culturally engrained medical concepts (Walach and Jonas,
2004). Apart from methodological issues, this might be the rea-
son why a number of variables (e.g., neuroticism) which have
been found to be involved in placebo responsiveness in the 1950s
and 60s have rarely been implicated since (but cf. Darragh et al.,
2014).
One of the most intriguing notions of the presented research
is the role of the control group in placebo experiments. A num-
ber of the constructs identified here warrant a deeper engagement
with the nature of this experimental aspect, as has been dis-
cussed before, e.g., on the topic of bias correction (Handley et al.,
2011). As another example, the induction of optimism can lead
to significant analgesia in groups not receiving any treatment at
all (Hanssen et al., 2013). The same applies for self-efficacy in
motion sickness (Eden and Zuk, 1995; Horing, 2013). It may
be that the question of placebo responsiveness is malformed:
That it is not about identifying who responds best to placebo,
but how to create a paradigm that best reinforces aspects like
optimism and self-efficacy, treatment given or not. When mem-
bers of the control group are being told “you will not get any
treatment before the retest. . .,” it might as well imply, “. . . so
however you deal with the symptoms at retest is entirely up to
you.” It seems worthwhile to not only look at what happens in
the group receiving the placebo treatment, but to take the time
to examine why specific symptoms change in the control group,
in order to figure out why placebos are effective at reducing
those symptoms at all. Not the least due to ethical constraints,
this genuinely psychosomatic question has only rarely been
addressed.
To conclude, despite the repeated and widely received empha-
sis on the necessity of adequate controls (Hróbjartsson, 2002;
Kaptchuk et al., 2008; Hróbjartsson et al., 2011), studies are often
ill-suited to provide answers concerning predictors of the PR.
Control groups are omitted either by design, or by insufficient
consideration in statistical analysis. In the latter case, many stud-
ies could be revisited to perform post-hoc analyses on response
prediction, particularly involving readily available parameters like
sex. Keeping in mind the complex interactions of the concrete
experimental designs with the respective predictors, a number
of variables have been repeatedly involved. It seems worthwhile
to include the identified variables in future studies—especially,
independent replication of some of the more frequently men-
tioned parameters is needed. Specifically, promising variables
are goal-seeking, self-efficacy, self-esteem, locus of control, and
optimism; desire for control and restraint; fun and sensation
seeking, and neuroticism; participants’ sex (or possibly gender);
the val158met-polymorphism; suggestibility, beliefs in expecta-
tion biases, body consciousness and baseline symptom severity.
At this point, it seems feasible to employ confirmatory analy-
ses involving a priori defined constructs and appropriate error
correction.
REFERENCES
Aslaksen, P. M., Bystad, M., Vambheim, S. M., and Flaten, M. A. (2011).
Gender differences in placebo analgesia: event-related potentials and emo-
tional modulation. Psychosom. Med. 73, 193–199. doi: 10.1097/PSY.0b013e3182
080d73
Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavioral change.
Psychol. Rev. 84, 191–215. doi: 10.1037/0033-295X.84.2.191
Benedetti, F. (2009). Placebo Effects: Understanding the Mechanisms in Health and
Disease. New York, NY: Oxford University Press.
Bjorkedal, E., and Flaten, M. A. (2011). Interaction between expectancies and drug
effects: an experimental investigation of placebo analgesia with caffeine as an
active placebo. Psychopharmacology (Berl) 215, 537–548. doi: 10.1007/s00213-
011-2233-4
Bjorkedal, E., and Flaten, M. A. (2012). Expectations of increased and decreased
pain explain the effect of conditioned pain modulation in females. J. Pain Res.
5, 289–300. doi: 10.2147/JPR.S33559
Bootzin, R. R., and Caspi, O. (2002). “Explanatory mechanisms for placebo effects:
cognition, personality and social learning,” in The Science of the Placebo: Toward
an Interdisciplinary Research Agenda, 1st Edn., ed H. A. Guess (London: BMJ
Books), 108–132.
Brockner, J. (1988). Self-Esteem at Work: Research, Theory and Practice. Lexington,
KY: D.C. Heath & Co.
Brockner, J., and Swap, W. C. (1983). Resolving the relationships between placebos,
misattribution, and insomnia: an individual-differences perspective. J. Pers. Soc.
Psychol. 45, 32–42. doi: 10.1037/0022-3514.45.1.32
Brody, H., and Brody, D. (2000). The Placebo Response: How You Can Release the
Body’s Inner Pharmacy for Better Health. New York, NY: Harper.
Darragh, M., Booth, R. J., and Consedine, N. S. (2014). Investigating the “placebo
personality” outside the pain paradigm. J. Psychosom. Res. 76, 414–421. doi:
10.1016/j.jpsychores.2014.02.011
David, J. P., Green, P. J., Martin, R., and Suls, J. (1997). Differential roles of neuroti-
cism, extraversion, and event desirability for mood in daily life: an integrative
model of top-down and bottom-up influences. J. Pers. Soc. Psychol. 73, 149–159.
doi: 10.1037/0022-3514.73.1.149
de la Fuente-Fernandez, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., and
Stoessl, A. J. (2001). Expectation and dopamine release: mechanism of the
placebo effect in Parkinson’s disease. Science 293, 1164–1166. doi: 10.1126/sci-
ence.1060937
de la Fuente-Fernandez, R., and Stoessl, A. J. (2002). The placebo effect
in Parkinson’s disease. Trends Neurosci. 25, 302–306. doi: 10.1016/S0166-
2236(02)02181-1
Frontiers in Psychology | Psychology for Clinical Settings October 2014 | Volume 5 | Article 1079 | 8
Horing et al. Placebo response prediction: systematic review
De Pascalis, V., Chiaradia, C., and Carotenuto, E. (2002). The contribution of sug-
gestibility and expectation to placebo analgesia phenomenon in an experimental
setting. Pain 96, 393–402. doi: 10.1016/S0304-3959(01)00485-7
Eden, D., and Zuk, Y. (1995). Seasickness as a self-fulfilling prophecy: raising
self-efficacy to boost performance at sea. J. Appl. Psychol. 80, 628–635. doi:
10.1037/0021-9010.80.5.628
Enck, P., Bingel, U., Schedlowski, M., and Rief, W. (2013). The placebo response
in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov. 12,
191–204. doi: 10.1038/nrd3923
Enck, P., Klosterhalfen, S., Weimer, K., Horing, B., and Zipfel, S. (2011). The
placebo response in clinical trials: more questions than answers. Philos. Trans.
R. Soc. Lond. B Biol. Sci. 366, 1889–1895. doi: 10.1098/rstb.2010.0384
Fillmore, M. T., Carscadden, J. L., and Vogel-Sprott, M. (1998). Alcohol, cognitive
impairment and expectancies. J. Stud. Alcohol 59, 174–179.
Finniss, D. G., Kaptchuk, T. J., Miller, F., and Benedetti, F. (2010). Biological,
clinical, and ethical advances of placebo effects. Lancet 375, 686–695. doi:
10.1016/S0140-6736(09)61706-2
Frank, J. D., and Frank, J. B. (1973). Persuasion and Healing: a Comparative Study
of Psychotherapy. Baltimore, MD: Johns Hopkins.
Geers, A. L., Helfer, S. G., Kosbab, K., Weiland, P. E., and Landry, S. J. (2005a).
Reconsidering the role of personality in placebo effects: dispositional opti-
mism, situational expectations, and the placebo response. J. Psychosom. Res. 58,
121–127. doi: 10.1016/j.jpsychores.2004.08.011
Geers, A. L., Kosbab, K., Helfer, S. G., Weiland, P. E., and Wellman, J. A.
(2007). Further evidence for individual differences in placebo respond-
ing: an interactionist perspective. J. Psychosom. Res. 62, 563–570. doi:
10.1016/j.jpsychores.2006.12.005
Geers, A. L., Rose, J. P., Fowler, S. L., Rasinski, H. M., Brown, J. A., and Helfer,
S. G. (2013). Why does choice enhance treatment effectiveness? Using placebo
treatments to demonstrate the role of personal control. J. Pers. Soc. Psychol. 105,
549–566. doi: 10.1037/a0034005
Geers, A. L., Weiland, P. E., Kosbab, K., Landry, S. J., and Helfer, S. G. (2005b). Goal
activation, expectations, and the placebo effect. J. Pers. Soc. Psychol. 89, 143–159.
doi: 10.1037/0022-3514.89.2.143
Geers, A. L., Wellman, J. A., Fowler, S. L., Helfer, S. G., and France, C. R. (2010).
Dispositional optimism predicts placebo analgesia. J. Pain 11, 1165–1171. doi:
10.1016/j.jpain.2010.02.014
Grizzle, J. E. (1965). The two-period change-over design and its use in clinical trials.
Biometrics 21, 467–480. doi: 10.2307/2528104
Gryll, S. L., and Katahn, M. (1978). Situational factors contributing to the
placebo effect. Psychopharmacology (Berl) 57, 253–261. doi: 10.1007/BF00
426747
Hall, K. T., Lembo, A. J., Kirsch, I., Ziogas, D. C., Douaiher, J., Jensen,
K. B., et al. (2012). Catechol-O-methyltransferase val158met polymorphism
predicts placebo effect in irritable bowel syndrome. PLoS ONE 7:e48135. doi:
10.1371/journal.pone.0048135
Handley, I. M., Fowler, S. L., Rasinski, H. M., Helfer, S. G., and Geers, A.
L. (2011). Beliefs about expectations moderate the influence of expectations
on pain perception. Int. J. Behav. Med. 20, 52–58. doi: 10.1007/s12529-011-
9203-4
Hanssen, M. M., Peters, M. L., Vlaeyen, J. W., Meevissen, Y. M., and Vancleef, L.
M. (2013). Optimism lowers pain: evidence of the causal status and underlying
mechanisms. Pain 154, 53–58. doi: 10.1016/j.pain.2012.08.006
Hanssen,M.M., Vancleef, L.M., Vlaeyen, J.W., and Peters,M. L. (2014).More opti-
mism, less pain! The influence of generalized and pain-specific expectations on
experienced cold-pressor pain. J. Behav. Med. 37, 47–58. doi: 10.1007/s10865-
012-9463-8
Heatherton, T. F., Polivy, J., and Herman, C. P. (1989). Restraint and internal
responsiveness: effects of placebo manipulations of hunger state on eating.
J. Abnorm. Psychol. 98, 89–92. doi: 10.1037/0021-843X.98.1.89
Hoffman, G. A., Harrington, A., and Fields, H. L. (2005). Pain and the
placebo: what we have learned. Perspect. Biol. Med. 48, 248–265. doi:
10.1353/pbm.2005.0054
Horing, B. (2013). Placebo Effects and Their Prediction Across Multiple
Experimentally Induced Symptoms: Motion Sickness, Cutaneous Heat and
Cold Pain, and Rectal Distension Pain. Doctoral dissertation, Eberhard Karls
University, Tübingen, Germany.
Horing, B., Weimer, K., Schrade, D., Muth, E. R., Scisco, J. L., Enck, P., et al.
(2013). Reduction of motion sickness with an enhanced placebo instruction:
an experimental study with healthy participants. Psychosom. Med. 75, 497–504.
doi: 10.1097/PSY.0b013e3182915ee7
Hróbjartsson, A. (2002). What are the main methodological problems in the esti-
mation of placebo effects? J. Clin. Epidemiol. 55, 430–435. doi: 10.1016/S0895-
4356(01)00496-6
Hróbjartsson, A., and Gotzsche, P. C. (2010). Placebo interventions for all clini-
cal conditions. Cochrane Database Syst. Rev. CD003974. doi: 10.1002/14651858.
CD003974.pub3
Hróbjartsson, A., Kaptchuk, T. J., andMiller, F. G. (2011). Placebo effect studies are
susceptible to response bias and to other types of biases. J. Clin. Epidemiol. 64,
1223–1229. doi: 10.1016/j.jclinepi.2011.01.008
Kaptchuk, T. J., Kelley, J. M., Deykin, A., Wayne, P. M., Lasagna, L. C., Epstein, I. O.,
et al. (2008). Do “placebo responders” exist? Contemp. Clin. Trials 29, 587–595.
doi: 10.1016/j.cct.2008.02.002
Kong, J., Spaeth, R., Cook, A., Kirsch, I., Claggett, B., Vangel, M., et al. (2013). Are
all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and
their association. PLoS ONE 8:e67485. doi: 10.1371/journal.pone.0067485
Leuchter, A. F., McCracken, J. T., Hunter, A. M., Cook, I. A., and Alpert, J.
E. (2009). Monoamine oxidase a and catechol-o-methyltransferase functional
polymorphisms and the placebo response in major depressive disorder. J. Clin.
Psychopharmacol. 29, 372–377. doi: 10.1097/JCP.0b013e3181ac4aaf
Levine, J. D., Gordon, N. C., Bornstein, J. C., and Fields, H. L. (1979). Role of
pain in placebo analgesia. Proc. Natl. Acad. Sci. U.S.A. 76, 3528–3531. doi:
10.1073/pnas.76.7.3528
Levine, J. D., Gordon, N. C., and Fields, H. L. (1978). The mechanism of placebo
analgesia. Lancet 2, 654–657. doi: 10.1016/S0140-6736(78)92762-9
Lyby, P. S., Aslaksen, P. M., and Flaten, M. A. (2010). Is fear of pain
related to placebo analgesia? J. Psychosom. Res. 68, 369–377. doi:
10.1016/j.jpsychores.2009.10.009
Moerman, D. E. (2000). Cultural variations in the placebo effect: ulcers,
anxiety, and blood pressure. Med. Anthropol. Q. 14, 51–72. doi:
10.1525/maq.2000.14.1.51
Morton, D. L., Watson, A., El-Deredy, W., and Jones, A. K. (2009). Reproducibility
of placebo analgesia: effect of dispositional optimism. Pain 146, 194–198. doi:
10.1016/j.pain.2009.07.026
Ober, K., Benson, S., Vogelsang, M., Bylica, A., Gunther, D., Witzke, O., et al.
(2011). Plasma noradrenaline and state anxiety levels predict placebo response
in learned immunosuppression. Clin. Pharmacol. Ther. 91, 220–226. doi:
10.1038/clpt.2011.214
Parkhouse, J. (1963). Placebo reactor. Nature 199:308. doi: 10.1038/199308a0
Pecina, M., Azhar, H., Love, T. M., Lu, T., Fredrickson, B. L., Stohler, C. S., et al.
(2013). Personality trait predictors of placebo analgesia and neurobiological
correlates. Neuropsychopharmacology 38, 639–646. doi: 10.1038/npp.2012.227
Petrovic, P. (2008). Placebo analgesia and nocebo hyperalgesia–two sides of the
same coin? Pain 136, 5–6. doi: 10.1016/j.pain.2008.03.004
Petrovic, P., Dietrich, T., Fransson, P., Andersson, J., Carlsson, K., and Ingvar,
M. (2005). Placebo in emotional processing–induced expectations of anxiety
relief activate a generalized modulatory network. Neuron 46, 957–969. doi:
10.1016/j.neuron.2005.05.023
Poulton, E. C., and Freeman, P. R. (1966). Unwanted asymmetrical trans-
fer effects with balanced experimental designs. Psychol. Bull. 66, 1–8. doi:
10.1037/h0023427
Rothbart, M. K. (2007). Temperament, development, and personality. Curr. Dir.
Psychol. Sci. 16, 207–212. doi: 10.1111/j.1467-8721.2007.00505.x
Schweinhardt, P., Seminowicz, D. A., Jaeger, E., Duncan, G. H., and Bushnell, M.
C. (2009). The anatomy of the mesolimbic reward system: a link between per-
sonality and the placebo analgesic response. J. Neurosci. 29, 4882–4887. doi:
10.1523/JNEUROSCI.5634-08.2009
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A.,
and Zubieta, J. K. (2007). Individual differences in reward responding
explain placebo-induced expectations and effects. Neuron 55, 325–336. doi:
10.1016/j.neuron.2007.06.028
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., and Zubieta,
J. K. (2008). Placebo and nocebo effects are defined by opposite opioid and
dopaminergic responses. Arch. Gen. Psychiatry 65, 220–231. doi: 10.1001/arch-
genpsychiatry.2007.34
Shapiro, A. K. (1971). “Placebo effects inmedicine, psychotherapy, and psychoanal-
ysis,” inHandbook of Psychotherapy and Behavior Change: an Empirical Analysis,
eds A. E. Bergin and S. L. Garfield (New York, NY: Wiley), 439–473.
www.frontiersin.org October 2014 | Volume 5 | Article 1079 | 9
Horing et al. Placebo response prediction: systematic review
Snyder, M., and Ickes, W. (1985). “Personality and social behavior,” in Handbook
of Social Psychology, 3rd Edn., eds G. Lindzey and E. Aronson (New York, NY:
Random House), 883–948.
Staats, P. S., Staats, A., and Hekmat, H. (2001). The additive impact of anxiety
and a placebo on pain. Pain Med. 2, 267–279. doi: 10.1046/j.1526-4637.2001.
01046.x
Thompson, J. J., Ritenbaugh, C., and Nichter, M. (2009). Reconsidering the placebo
response from a broad anthropological perspective. Cult. Med. Psychiatry 33,
112–152. doi: 10.1007/s11013-008-9122-2
Vase, L., Robinson, M. E., Verne, G. N., and Price, D. D. (2003). The contri-
butions of suggestion, desire, and expectation to placebo effects in irritable
bowel syndrome patients. An empirical investigation. Pain 105, 17–25. doi:
10.1016/S0304-3959(03)00073-3
Walach, H., and Jonas, W. B. (2004). Placebo research: the evidence base for
harnessing self-healing capacities. J. Altern. Complement. Med. 10 (Suppl. 1),
S103–S112. doi: 10.1089/1075553042245773
Whalley, B., Hyland, M. E., and Kirsch, I. (2008). Consistency of the placebo effect.
J. Psychosom. Res. 64, 537–541. doi: 10.1016/j.jpsychores.2007.11.007
Conflict of Interest Statement: Work of the authors is supported by the
Volkswagen Foundation Grant No. I/83 805 from Volkswagen Foundation
(Hannover, Germany), a grant from the Deutsche Forschungsgemeinschaft (DFG
En 50/30-1) within the DFG Centre Grant FOR 1328, and the Institutional Strategy
of the University of Tübingen (DFG ZUK 63). The authors also acknowledge sup-
port by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of
the University of Tübingen. The authors declare that the research was conducted in
the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 14 July 2014; accepted: 08 September 2014; published online: 01 October
2014.
Citation: Horing B, Weimer K, Muth ER and Enck P (2014) Prediction of placebo
responses: a systematic review of the literature. Front. Psychol. 5:1079. doi: 10.3389/
fpsyg.2014.01079
This article was submitted to Psychology for Clinical Settings, a section of the journal
Frontiers in Psychology.
Copyright © 2014 Horing, Weimer, Muth and Enck. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Psychology | Psychology for Clinical Settings October 2014 | Volume 5 | Article 1079 | 10
